Shots:
- Thermo Fisher has entered into a definitive agreement to acquire Clario, enhancing its digital & data capabilities in clinical research
- As per the deal, Thermo Fisher Scientific will acquire Clario for $8.875B in cash, with an additional $125M due in January 2027 & ~$400M in performance-based earnouts for 2026–2027; closing is expected mid-2026, after which Clario will join its Laboratory Products & Biopharma Services segment
- Clario’s platform complements Thermo Fisher’s clinical research capabilities by digitally integrating endpoint data from devices, sites, & pts, enabling faster, data-driven decisions across all phases of drug development
Ref: Thermo Fisher | Image: Clario| Press Release
Related News:- Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
